<p>What the Food and Drug Administration calls a 'breakthrough' drug is often not the same as what a layperson would call a breakthrough, a new study shows.</p>
The FDA has approved a drug already indicated for COPD treatment for the long-term, once-daily maintenance of asthma in individuals 12 years old and older.
The FDA has changed the requirements for prescribing, dispensing, and receiving a certain schizophrenia medication due to growing concerns of the risk of neutropenia.
The FDA has granted Rare Pediatric Disease Designation for the medication, a therapy for patients with Duchenne muscular dystrophy who are open to skipping exon 51.